Introduction
============

Congenital malformations of the eyeball appear to occur more frequently in certain countries like India and Sri Lanka, accounting for approximately 25% of cases of visual impairment and blindness \[[@r1]\]. Ocular coloboma is a congenital, common, and heterogeneous malformation which includes a spectrum of anomalies ranging from iris coloboma to clinical anophthalmos. Ocular coloboma, as an isolated defect, is usually inherited as an autosomal dominant disorder, although autosomal recessive inheritance also occurs. Coloboma is a hole in one of the structures of the eye, such as the iris, retina, choroid, or optic disc. If coloboma is present both in iris and retina it is known as irido-fundal coloboma. According to coloboma location in the retina and whether it involves the optic nerve or not, coloboma is classified into six types by Gopal \[[@r2]\]: (I) this involves the optic nerve and is the biggest type of coloboma ([Figure 1](#f1){ref-type="fig"}). Vision is generally quite poor in this type; (II) involves the optic nerve but it is smaller than type I, so vision is poor but not as bad as in type I coloboma; (III) this just misses the optic nerve ([Figure 2](#f2){ref-type="fig"}) so vision can be quite good. However if associated with increased axial length and resulting high myopic refractive error (spectacle number) the vision can be decreased; (IV) this coloboma involves only the optic nerve but not much retina that surrounds it. Vision can be good to average depending on how much the optic nerve is distorted; (V) this coloboma is in the periphery and does not involve the optic nerve as well as the main area of the retina ([Figure 3](#f3){ref-type="fig"}). As far as vision is considered it is quite good in this type and any problem in vision might not be noticed by the patient; (VI) these are partially aborted attempts at forming coloboma. Vision is unaffected in this type of coloboma.

![Fundus photograph in type I coloboma.](mv-v17-1414-f1){#f1}

![Fundus photograph in type III coloboma.](mv-v17-1414-f2){#f2}

![Fundus photograph in type V coloboma.](mv-v17-1414-f3){#f3}

The estimated prevalence of coloboma is 1 in 10,000 in the world population \[[@r3],[@r4]\]. Coloboma associated with other syndromes may cause up to 10% of the childhood blindness \[[@r5]\]. The genetic basis of coloboma remains elusive. Recent studies suggest that earlier developmental processes in eye are controlled by a complex network of transcriptional factors, cell cycle regulators and diffusible signaling molecules \[[@r6]\].

Paired box gene 6 (*PAX6*), a member of the paired box family of transcription factors, has been identified as a key regulator of eye development in both vertebrates and invertebrates \[[@r7]-[@r9]\]. During early mouse eye development, expression of Pax6 has been shown in the presumptive lens ectoderm, lens placode, lens vesicle and optic vesicle \[[@r10],[@r11]\]. At later stages, Pax6 is found in epithelia of conjunctiva, cornea, lens, and ciliary body and in the neural retina \[[@r12],[@r13]\]. In humans, mutations in *PAX6* have been demonstrated in several patients with aniridia \[[@r14]-[@r17]\], a panocular disease that is associated with iris hypoplasia, corneal opacification, cataract, foveal dysplasia, and other diseases \[[@r18]\].

*PAX6* is located on chromosome 11p13 acts as transcriptional regulator of other genes that are associated with coloboma. This gene contains 14 exons and encodes a 422-amino acid polypeptide containing two DNA-binding domains, a bipartite paired domain, and a paired type homeodomain \[[@r19]\]. The paired domain, which is coded by exons 5--7 of *PAX6*, has two subdomains: the relatively conserved 74-amino acid NH~2~-terminal sub-domain and the more divergent 54-amino acid COOH-terminal subdomain. The latter sub-domain is a common place for mutations \[[@r19],[@r20]\]. Currently there are around 500 mutations that have been reported (Human PAX6 Allelic Variant Database ([HPAVD](http://pax6.hgu.mrc.ac.uk/)). Most *PAX6* nonsense mutations lead to aniridia, while missense mutations are related to foveal hypoplasia, congenital cataracts, or anterior segment anomalies \[[@r21],[@r22]\].

In this preliminary pilot study we have screened *PAX6* for mutations in irido-fundal coloboma patients (n=30) and normal healthy controls (n=30).

Methods
=======

Patient selection and DNA isolation
-----------------------------------

The research followed the tenets of the Declaration of Helsinki in the treatment of the subject reported herein. The study was approved by institutional review board (IRB \# IRB00006862) of All India Institute of Medical Sciences (AIIMS) and all participants gave their written informed consent. A total of thirty coloboma patients presented at the Dr. R. P. Centre for Ophthalmic Sciences (AIIMS, New Delhi, India) were enrolled in this study. Clinical evaluation involved fundoscopy (direct and indirect ophthalmoscopy), slitlamp-biomicroscopy, and retinoscopy. Of these patients, 18 were males and 12 were females. Mean age of presentation was 16.32 years. Diagnosis of coloboma involved the presence of deficient of iris tissue and presence of coloboma in retina on clinical examination. All cases were sporadic without any family history. All cases secondary to causes like trauma etc. were excluded from the study.

After informed consent, detailed personal, medical, and occupational history was collected and a family tree up to three generations was drawn. Thirty ethnically matched normal individuals without any ocular disorder were enrolled as controls. Health information was obtained from controls through the questionnaire; all underwent ophthalmological examination and a blood sample (5 ml) was collected in EDTA (EDTA) vacutainers (Greiner Bio-One, GmbH, Frickenhausen, German**y**) from patients and controls for DNA extraction. DNA was extracted from whole blood samples of all patients and controls using the phenol-chloroform method.

Polymerase chain reaction (PCR) and DNA Sequencing
--------------------------------------------------

All coding regions of *PAX6* including exon-intron junctions were amplified using a set of eight oligonucleotide primers ([Table 1](#t1){ref-type="table"}). These primers were designed using NCBI [PRIMER3](http://www.ncbi.nlm.nih.gov/tools/primer-blast/) program.

###### Primers used for *PAX6* amplification.

  **Sample number**   **Forward primer sequence (5′-3′)**   **Reverse primer sequence (5′-3′)**   **Product size (bp)**   **Annealing temp (°C)**
  ------------------- ------------------------------------- ------------------------------------- ----------------------- -------------------------
  1                   GGAGTTCAGGCCTACCTGATGCAG              GAGAAGAGCCAAGCAAACGCCCTC              313                     55
  2                   CGCCGAGGTTGGCACAGGTT                  AGCATGGGCTGGGGAGAGCA                  710                     55
  3                   CGTTTTGATGCATCTTCAGGCAGTG             GGGCATTCCTCTCTGTTCCCCCA               703                     62
  4                   TGGTGAAGGACCCCCTCCGC                  ACACACACGCACCCACCAGC                  647                     61
  5                   ACCAGGCCCCTTTTGGAGGCT                 TGGCATTCAGTGACCTTTCTGTGGC             554                     62
  6                   GGAGTGGGGAGGTGGGAACCA                 AGGCCCTGAGCCACTCCTCAC                 837                     60
  7                   AGCTGTGGCCAGTGGAAGGAC                 TGGGCCCCCTACTGAGCTTCG                 636                     62
  8                   TCCTTTGGATTGGGGTGGGGG                 CGTGGCAAAGCTTGTTGATCATGG              713                     62

Each reaction was performed in a 25 µl mixture containing 0.2 µM each primer, 0.5 U Taq DNA polymerase, 2.5 µl of 10× PCR buffer (Biogene, New Delhi, India) with 2.5 mM MgCl~2~, and approximately 100 ng genomic DNA. PCR was performed in thermal cycler (My Cycler; BioRad, Gurgaon, India) under the conditions shown in [Table 1](#t1){ref-type="table"}.

All PCR products were analyzed on 1.8% agarose gel stained with ethidium-bromide (EtBr; 10 mg/ml). Agarose gels were analyzed using the Gel Documentation System (Applied Biosystems, Carlsbad, CA). Amplified PCR products were purified using gel/PCR DNA fragments extraction kit (Catalog number DF100; Geneaid Biotech Ltd., Sijhih City, Taiwan). Purified PCR products were outsourced for sequencing at Molecular Cloning Laboratories ([MCLAB](http://www.mclab.com/product.php?productid=19071), South San Francisco, CA).

DNA sequences were compared with the human [PAX6](http://www.ensembl.org/Homo_sapiens/Gene/Sequence?g=ENSG00000007372;r=11%3A31806340-31839509) reference sequence.

Insilico analysis for predicting pathogenicity of mutations
-----------------------------------------------------------

An [improved splice site predictor tool](http://www.fruitfly.org/seq_tools/splice.html) \[[@r23]\] was used for predicting the effect of an intronic nucleotide change on splicing of *PAX6* mRNA.

Results
=======

DNA sequence analysis of patients and controls revealed a total of three nucleotide changes. Of which one was neutral/synonymous and novel change. The remaining two changes were intronic, one of which was novel. Details of these cases are tabulated ([Table 2](#t2){ref-type="table"}).

###### Clinical manifestations of cases with irido-fundal coloboma.

  **Patient ID**   **Age (years)**   **Sex**   **Iridofundla coloboma type**                                   **Axial length (RE;LE)**   **Visual acuity (RE;LE)**   **Treatment**
  ---------------- ----------------- --------- --------------------------------------------------------------- -------------------------- --------------------------- -----------------------------------------------
  IFC1             15                M         B/L Type II IFC                                                 21.62;21.59                3/60; 3/60                  B/L laser
  IFC2             7                 F         B/LType I IFC + microophthalmia +microcornea + nystagamus       24.26;25.50                2/60; 1/60                  Laser not possible due to extreme microcornea
  IFC3             17                F         LE Inferonasal + IFC type III                                   20.64;20.33                6/6; PL +ve                 LE laser
  IFC4             7                 M         B/L IFC type I                                                  19.25;22.20                PL+; PL +ve                 No laser done
  IFC5             10                F         B/L microophthalmia +microcornea + nystagamus + type II IFC     20.21;20.85                1/60;1/60                   No laser done due to extreme microcornea
  IFC6             27                M         B/L Nystagymus + type II IFC                                    26.22; 22.71               FCCF;FCCF                   B/L laser
  IFC7             13                F         RE IFC type II + amblyopia                                      24.81;22.69                FCCF;6/12                   RE laser
  IFC8             28                M         LE type III IFC                                                 22.84;21.77                6/6; 6/60                   L/E laser
  IFC9             26                M         RE IFC type III                                                 26.11;22.60                6/24; 6/6                   RE laser
  IFC10            16                F         B/L IFC type I                                                  24.50;24.60                1/60;2/60                   B/L laser
  IFC11            10                F         RE IFC type III                                                 21.54;20.70                Patient non-cooperative     RE laser
  IFC12            7                 M         RE IFC; L Iris coloboma; B/L microcornea                        20.01; 20.39               FCCF;6/60                   B/L laser
  IFC13            3                 M         B/L (microophthalmia +microcornea + distichiasis + IFC type I   20.08;22.00                FCCF;1/60                   B/L laser
  IFC14            20                M         RE IFC type II coloboma                                         25.25;23.50                HMCF/6/24                   R/L laser
  IFC15            5                 M         B/L type II IFC                                                 21.91/21.02                6/60; 6/36                  B/L laser
  IFC16            11                M         B/L microophthalmia + type II IFC                               22.65;21.80                3/60;6/60                   B/L laser
  IFC17            11                M         B/L type I IFC with squint                                      18.25; 22.45               1/60; 2/60                  B/L laser
  IFC18            9                 M         B/L microophthalmia + IFC type I                                22.45; 23.10               PL+; 1/60                   B/L laser
  IFC19            19                F         B/L microcornea + type II IFC                                   22.12; 22.70               1/60; 3/60                  B/L laser
  IFC20            28                F         B/L IFC type III + nystagamus                                   26.18; 27.66               HMCF/6/60                   B/L laser
  IFC21            15                M         LE IFC type II                                                  22.73; 26.73               6/6; HMCF                   L laser
  IFC22            33                M         B/L IFC type III                                                21.35; 21.50               6/36; 6/36                  B/L laser
  IFC23            33                M         B/L IFC type IV                                                 24.09; 24.24               6/60; 1/60                  B/L laser
  IFC24            30                M         B/L IFC type IV + microcornea + nystagymous                     29.55; 24.99               HMCF; FC2M                  B/L laser
  IFC25            25                M         RE type I IFC; LE type V IFC                                    26.81; 23.71               HMCF/6/6                    B/L laser
  IFC26            17                M         B/L type III IFC                                                24.35; 24.50               6/18, 6/18                  B/L laser
  IFC27            14                M         B/L IFC Type I                                                  26.25; 25.90               1/60; 2/60                  B/L laser
  IFC28            15                M         LE type III IFC + Microcornea                                   22.50; 22.24               6/6;6/60                    LE laser
  IFC29            6                 F         RE IFC type III; LE type II IFC                                 24.45; 25.50               6/60; 2/60                  B/L laser
  IFC30            12                M         B/L type V IFC                                                  23.50;22.80                6/9; 6/12                   B/L laser

Key: IFC represents Iridofundal coloboma; LE represents Left eye; RE represents Right eye; FCCF represents Finger counting close to face; HMCF represents Hand motion close to face; PL represents Perception of light.

g.31815391Cytosine\>Thymine
---------------------------

A novel single nucleotide change from cytosine (C) to thymine (T) at genomic position g. 31815391 ([Figure 4](#f4){ref-type="fig"}) was present in one case but absent in controls. The alteration is located in intron 9 (IVS9+40). This change was registered at GenBank with accession number [HQ397715](http://www.ncbi.nlm.nih.gov/nuccore/HQ397715).

![DNA sequence of *PAX6* equivalent to g.31815399 to 31815385. **A**: The reference sequence derived from the control is shown. **B**: The sequence derived from patient shows a heterozygous C\>T mutation at g.31815391.](mv-v17-1414-f4){#f4}

g.31823250 Thymine\>Guanine
---------------------------

In this mutation a single nucleotide T was replaced by guanine (G) at genomic position g.31823250; cDNA position c.216; codon 72 resulted in a codon change GGT\>GGG which predicts a synonymous change p.Gly72Gly (p.G72G; [Figure 5](#f5){ref-type="fig"}). This change was present as heterozygous change in 29 cases and 20 controls; and as a homozygous change in one case. This change was novel and registered at GenBank with accession number [HQ397714](http://www.ncbi.nlm.nih.gov/nuccore/HQ397714).

![DNA sequence of *PAX6* equivalent to codon 71--75. **A**: The reference sequence derived from the control shows the heterozygous c.216T\>G change which predicts a codon change from GGT\>GGG and p.G72G mutation. **B**: The sequence derived from another patient shows a homozygous p.G72G mutation.](mv-v17-1414-f5){#f5}

g.31812215Thymine\>Guanine
--------------------------

A single nucleotide change from T to G at genomic position g.31812215 ([Figure 6](#f6){ref-type="fig"}) was present in six cases and one control. The alteration is located in intron 12 (IVS13--42).

![DNA sequence of *PAX6* equivalent to g.31812220 to 31812209. **A**: The reference sequence derived from the control is shown. **B**: The sequence derived from patient shows a homozygous g.31812215T\>G mutation.](mv-v17-1414-f6){#f6}

Improved splice site prediction for both intronic changes showed that the location of these changes is not present at a splice site and may not create splicing error in the PAX6 protein.

Discussion
==========

The genetic basis of coloboma remains elusive. Recent studies suggest that earlier developmental process in the eye are controlled by a complex network of transcriptional factors, cell cycle regulators, and diffusible signaling molecules \[[@r6]\]. Mutations in these genes may lead to ocular coloboma. It has been proposed that PAX6 acts as a transcriptional regulator of many other genes involved in ocular development. *PAX6* mutations have been identified in sporadic aniridia cases from different populations \[[@r17]\] as well as in familial aniridia cases \[[@r14]-[@r16]\]. In this study we have screened *PAX6* in irido-fundal coloboma patients and controls and we observed 3 changes (2 intronic changes and one synonymous/neutral change). However, no pathogenic *PAX6* mutation was identified in our patients.

Mutations in *PAX2* were identified in individuals with ocular coloboma in renal coloboma syndrome \[[@r24]\]. *PAX2* is a member of a multi-gene family containing a paired box domain that was identical in *Drosophila* and subsequently in vertebrates \[[@r25]\]. *PAX2* expression is critical for development of urogenital tract, central nervous system (CNS), inner ear, and optic nerve. Further studies suggest that *PAX2* mutations are not common in patients with isolated ocular coloboma and associated anomalies \[[@r26]\].

The absence of *PAX6* mutations in our study population suggests the involvement of other coloboma genes showed by Zhang et al. \[[@r27]\]. This study expands the SNP spectrum of *PAX6*, only rare variations which are not causative have been found. Since this is a pilot study in the north Indian population, our results should be confirmed in different populations by similar studies. However, the absence of *PAX6* mutations in selected population do not rule out the possibility of involvement of this gene in coloboma. Friling et al. \[[@r28]\] have shown the deletion of the whole gene (11p) in a patient with uveal colobomata. So there is still a possibility for *PAX6* to be involved in coloboma cases which can be detected by CGH array. As the frequency of the congenital blindness is more in Asian countries \[[@r18]\], where a majority of the population has vitamin A deficiency which is required for normal expression of several genes involved in ocular morphogenesis. Vitamin A is critical during eye development and optic fissure fails to close in vitamin A deficient embryos \[[@r29]\]. It has been reported that *Pitx2* expression is downregulated in vitamin A deficient embryos and this gene is required for optic fissure closure. Epidemiological evidences has shown the teratogenic effect of vitamin A deficiency during pregnancy. Thus screening of the candidate gene is required in large number of cases. Familial cases are required for determination of the underlying genetic loci accounting for this clinical phenotype which may lead to better understanding of disease pathogenesis in near future.
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